Hesperetin Liposomes for Cancer Therapy

Author(s): Joy Wolfram, Bronwyn Scott, Kathryn Boom, Jianliang Shen, Carlotta Borsoi, Krishna Suri, Rossella Grande, Massimo Fresta, Christian Celia, Yuliang Zhao, Haifa Shen, Mauro Ferrari

Journal Name: Current Drug Delivery

Volume 13 , Issue 5 , 2016

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Hesperetin is a compound from citrus fruit that has previously been found to exert anticancer activity through a variety of mechanisms. However, the application of hesperetin to cancer therapy has been hampered by its hydrophobicity, necessitating the use of toxic solubilizing agents. Here, we have developed the first liposome-based delivery system for hesperetin. Liposomes were fabricated using the thin-layer evaporation technique and physical and pharmacological parameters were measured. The liposomes remained stable for prolonged periods of time in serum and under storage conditions, and displayed anticancer efficacy in both H441 lung cancer cells and MDA-MB-231 breast cancer cells. Furthermore, the anticancer activity was not impaired in cells expressing the multidrug resistance protein 1 (MDR-1). In conclusion, the encapsulation of hesperetin in liposomes does not interfere with therapeutic efficacy and provides a biocompatible alternative to toxic solubilizing agents, thereby enabling future clinical use of this compound for cancer therapy.

Keywords: Breast cancer, Drug delivery, Flavanone, Lung cancer, MDR-1, Natural products.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 25 June, 2016
Page: [711 - 719]
Pages: 9
DOI: 10.2174/1567201812666151027142412
Price: $65

Article Metrics

PDF: 31